CS-101 for patients with beta-thalassemia
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a new treatment called CS-101 for people with beta-thalassemia who need regular blood transfusions. It aims to see if CS-101 can help reduce transfusion needs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 6 and 35 years old.
- You have been diagnosed with beta-thalassemia.
- You have needed at least 8 blood transfusions in the past year.
- You are generally healthy enough for the study procedures.
- You have not had a stem cell transplant or gene therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows up with people who already received the CS-101 injection in a previous trial to check its safety and how well it works over time.
This study follows up on people who have already received the CS-101 infusion in a previous trial. It aims to check how participants are doing over time. There are no restrictions to join if you already received CS-101.
This study checks on participants who previously received the experimental treatment CS-101. It aims to track their health over time to see how safe and effective the treatment is in the long run.
This gene therapy trial uses a modified virus to deliver a healthy gene into your own stem cells. The goal is to help your body make normal red blood cells so you may need fewer or no transfusions.
This trial tests a new gene-editing treatment called CS-101 for people with beta-thalassemia major who need regular blood transfusions. It aims to see if the treatment is safe and can reduce or eliminate the need for transfusions.
This early study tests the safety and potential benefit of the LentiRed gene-based drug in people with transfusion-dependent beta-thalassemia (TDT) who are planning an autologous stem cell transplant. It may help reduce the severity of anemia, but the main goal at this stage is to check safety and side effects.
Hear when a new Beta-Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.